PUBLICATIONS

Watt HL, Rachid Z, Jean-Claude BJ. The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries. J Signal Transduct. 2012: 282050. Available online

Al-Safadi S, Domarkas J, Han Y, Brahimi F, Jean-Claude BJ. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach. Anticancer Drugs. 2012, 23, 483-93. Article Link

Fang Y, Qiu Q, Domarkas J, Larroque-Lombard AL, Rao S, Rachid Z, Gibbs BF, Gao X, Jean-Claude BJ. Combi-targeting" mitozolomide: Conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer. Prostate. 2012, 72, 1273-85 Article Link

Ait-Tihyaty M, Rachid Z, Mihalcioiu C, Jean-Claude BJ. Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.. Breast Cancer Res Treat. 2012, 133, 217-26.

Larroque-Lombard, A.-L.; Todorova, M.; Qiu, Q.; Jean-Claude, B. J. Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA and MEK. Chemical Biology & Drug Design 2011, 77, 309318. Article Link

Huang, Y.; Rachid, Z.; Jean-Claude, B. J. O6-Methylguanine DNA Methyltransferase (MGMT) is a 3 Molecular Determinant for Potency of the DNA-Epidermal 4 Growth Factor Receptor (EGFR) Targeting Combi-Molecule ZRS1. Molecular Cancer Research 2011, 9, 320-331. Article Link

Golabi, N.; Rachid, Z.; Qiu, Q.; Huang, Y.; Jean-Claude, B. J. In Vitro and In Vivo Biodistribution of ZRS1, a Stabilized Type I N-Acetoxymethyl Carbamate-Containing Combi-Molecule. Drug. Metab. Lett. 2011, 5, 141-9. Article Link

Golabi, N.; Brahimi, F.; Huang, Y.; Rachid, Z.; Qiu, Q.; Larroque-Lombard, A.-L.; Jean-Claude, J. B. A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity. Journal of Pharmaceutical and Biomedical Analysis 2011, 56, 592-599. Article Link

Banerjee, R.; Huang, Y.; Qiu, Q.; James, J.; Belinsky, G.; Jean-Claude, B. J. The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle Cellular Signalling 2011, 4, 630-640. Article Link

Watt, H. L.; Rachid, Z.; Jean-Claude, B. J. Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting. J Neuro-Oncology 2010, 100, 345-361. Article Link

Todorova, M.; Larroque, A.-L.; Dauphin-Pierre, S.; Fang, Y. Q.; Jean-Claude, B. J. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Molecular Cancer Therapeutics 2010, 9, 869-882. Article Link

Larroque-Lombard, A. L.; Todorova, M.; Golabi, N.; Williams, C.; Jean-Claude, B. Synthesis and Uptake of Fluorescence-Labeled Combi-molecules by P-Glycoprotein-Proficient and -Deficient Uterine Sarcoma Cells MES-SA and MES-SA/DX5. J. Med. Chem. 2010, 53 2104-2113. Article Link

Banerjee, R.; Huang, Y.; McNamee, J. P.; Todorova, M. I.; Jean-Claude, B. J. The Combi-Targeting Concept: Selective Targeting of the Epidermal Growth Factor Receptor (EGFR)- and Her2-Expressing Cancer Cells by the Complex Combi-Molecule RB24 (NSC 741279). Journal of Pharmacology and Experimental Therapeutics 2010, 334, 9-20. Article Link

Rachid, Z.; MacPhee, M.; Williams, C.; Todorova, M.; Jean-Claude, B. J. Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2. Bioorg. Med. Chem. Lett. 2009, 19, 5505-5509. Article Link

Heravi, M.; Rachid, Z.; Goudarzi, A.; Schlisser, A.; Jean-Claude, B. J.; Radzioch, D.; Muanza, T. M. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. Anticancer Drugs 2009. Article Link

Qiu, Q.; Larroque, A. L.; Gibbs, B. F.; Fang, J. Y.; Lakhrissi, Y.; Soucy, J.-P.; Mzengeza, S.; Rachid, Z.; Jean-Claude, B. J. Molecular Analysis of the In Vivo Metabolism and Biodistribution of Metabolically and Non-Metabolically Activated Combi Molecules of the Triazene Class Drug Metabolism Letters 2009, 3, 1-9. Article Link

Barchechath, S.; Williams, C.; Saade, K.; Lauwagie, S.; Jean-Claude, B. Rational design of multitargeted tyrosine kinase inhibitors: a novel approach. Chemical Biology & Drug Design 2009, 73, 380-387. Article Link

Katsoulas, A.; Rachid, Z.; McNamee, J. P.; Williams, C.; Jean-Claude, B. J. Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia. Molecular Cancer Therapeutics 2008, 7, 1033-1043. Article Link

Larroque, A.-L.; Peori, B.; Williams, C.; Fang, Y. Q.; Qiu, Q.; Rachid, Z.; Jean-Claude, B. J. Synthesis of water soluble bis-triazenoquinazolines: an unusual predicted mode of binding to the epidermal growth factor receptor tyrosine kinase. Chemical Biology & Drug Design 2008, 71, 374-379. Article Link

Rachid, Z.; Katsoulas, A.; Williams, C.; Larroque, A. L.; McNamee, J.; Jean-Claude, B. J. Optimization of novel combi-molecules: identification of balanced and mixed bcr-abl/DNA targeting properties. Bioorg Med Chem Lett. 2007, 17, 4248-53. Article Link

Rachid, Z.; Brahimi, F.; Qiu, Q.; Williams, C.; Hartley, J. M.; Hartley, J. A.; Jean-Claude, B. J. Novel Nitrogen Mustard-Armed Combi-Molecules for the Selective Targeting of Epidermal Growth Factor Receptor Overexperessing Solid Tumors: Discovery of an Unusual Structure-Activity Relationship. Journal of Medicinal Chemistry 2007, 50, 2605-2608. Article Link

Qiu, Q.; Domarkas, J.; Banerjee, R.; Merayo, N.; Brahimi, F.; McNamee, J. P.; Gibbs, B. F.; Jean-Claude, B. J. The Combi-Targeting Concept: In vitro and In vivo Fragmentation of a Stable Combi-Nitrosourea Engineered to Interact with the Epidermal Growth Factor Receptor while Remaining DNA Reactive. Clinical Cancer Research 2007, 13, 331-340. Article Link

Qiu, Q.; Domarkas, J.; Banerjee, R.; Katsoulas, A.; McNamee, J. P.; Jean-Claude, B. J. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anti-Cancer Drugs 2007, 18, 171-177. Article Link

Merayo, N.; Rachid, Z.; Qiu, Q.; Brahimi, F.; Jean-Claude, B. J. The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo. Anti-Cancer Drugs 2006, 17, 165-171. Article Link

Domarkas, J.; Dudouit, F.; Williams, C.; Qiyu, Q.; Banerjee, R.; Brahimi, F.; Jean-Claude, B. J. The Combi-Targeting Concept: Synthesis of Stable Nitrosoureas Designed to Inhibit the Epidermal Growth Factor Receptor (EGFR). Journal of Medicinal Chemistry 2006, 49, 3544-3552. Article Link

Rachid, Z.; Brahimi, F.; Domarkas, J.; Jean-Claude, B. J. Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status. Bioorganic & Medicinal Chemistry Letters 2005, 15, 1135-1138. Article Link

Katsoulas, A.; Rachid, Z.; Brahimi, F.; McNamee, J.; Jean-Claude, B. J. Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl. Leukemia Research 2005, 29, 565-572. Article Link

Katsoulas, A.; Rachid, Z.; Brahimi, F.; McNamee, J.; Jean-Claude, B. J. Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias. Leukemia Research 2005, 29, 693-700. Article Link

Brahimi, F.; Rachid, Z.; McNamee, J. P.; Alaoui-Jamali, M. A.; Tari, A. M.; Jean-Claude, B. J. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: Evidence for enhancement of potency. Biochemical Pharmacology 2005, 70, 511-519.Article Link

Qiu, Q.; Dudouit, F.; Banerjee, R.; McNamee, J. P.; Jean-Claude, B. J. Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. Prostate (New York, NY, United States) 2004, 59, 13-21. Article Link

Matheson, S. L.; McNamee, J. P.; Wang, T.; Alaoui-Jamali, M. A.; Tari, A. M.; Jean-Claude, B. J. The combi-targeting concept: Dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. Journal of Pharmacology and Experimental Therapeutics 2004, 311, 1163-1170. Article Link

Matheson, S. L.; Brahimi, F.; Jean-Claude, B. J. The combi-targeting concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting \"combi-triazene\" SMA41. Biochemical Pharmacology 2004, 67, 1131-1138. Article Link

Matheson, S.; Qiu, Q.; Brahimi, F.; Dudouit, F.; Banerjee, R.; Rachid, Z.; Jean-Claude, B. J. Combi-molecules: a global approach towards better chemoselectivity of cytotoxic agents and chemoresistance of refractory tumors. Bulletin du Cancer 2004, 91, 911-915. Article Link

Jean-Claude, B. J. Chemosensitization to platinum-based anticancer drugs: Current trends and future prospects. DNA Repair in Cancer Therapy 2004, 51-71.

Brahimi, F.; Rachid, Z.; Qiu, Q.; McNamee, J. P.; Li, Y.-J.; Tari, A. M.; Jean-Claude, B. J. Multiple mechanisms of action of ZR2002 in human breast cancer cells: A novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. International Journal of Cancer 2004, 112, 484-491. Article Link

Banerjee, R.; Rachid, Z.; Qiu, Q.; McNamee, J. P.; Tari, A. M.; Jean-Claude, B. J. Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. British Journal of Cancer 2004, 91, 1066-1073. Article Link

Rachid, Z.; Katsoulas, A.; Brahimi, F.; Jean-Claude, B. J. Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase. Bioorganic & Medicinal Chemistry Letters 2003, 13, 3297-3300. Article Link

Rachid, Z.; Brahimi, F.; Katsoulas, A.; Teoh, N.; Jean-Claude, B. J. The Combi-Targeting Concept: Chemical Dissection of the Dual Targeting Properties of a Series of "Combi-Triazenes". Journal of Medicinal Chemistry 2003, 46, 4313-4321. Article Link

Qiu, Q.; Dudouit, F.; Matheson, S. L.; Brahimi, F.; Banerjee, R.; McNamee, J. P.; Jean-Claude, B. J. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemotherapy and Pharmacology 2003, 51, 1-10. Article Link

Matheson, S. L.; Mzengeza, S.; Jean-Claude, B. J. Synthesis of 1-[4-(m-tolylamino)-6-quinazolinyl]-3-[14C]methyltriazene: a radiolabeled probe for the combi-targeting concept. Journal of Labelled Compounds & Radiopharmaceuticals 2003, 46, 729-735. Article Link

Matheson, S. L.; McNamee, J. P.; Jean-Claude, B. J. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemotherapy and Pharmacology 2003, 51, 11-20. Article Link

Banerjee, R.; Rachid, Z.; McNamee, J.; Jean-Claude, B. J. Synthesis of a Prodrug Designed To Release Multiple Inhibitors of the Epidermal Growth Factor Receptor Tyrosine Kinase and an Alkylating Agent: A Novel Tumor Targeting Concept. Journal of Medicinal Chemistry 2003, 46, 5546-5551. Article Link

Brahimi, F.; Matheson, S. L.; Dudouit, F.; McNamee, J. P.; Tari, A. M.; Jean-Claude, B. J. Inhibition of epidermal growth factor receptor-mediated signaling by \"Combi-Triazene\" BJ2000, a new probe for Combi-Targeting postulates. Journal of Pharmacology and Experimental Therapeutics 2002, 303, 238-246. Article Link

Matheson, S. L.; McNamee, J.; Jean-Claude, B. J. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. Journal of Pharmacology and Experimental Therapeutics 2001, 296, 832-840. Article Link

Dumont-Hornebeck, B.; Strube, Y. N.; Vasilescu, D.; Jean-Claude, B. J. Design and synthesis of a novel water-soluble benzotetrazepinone. Bioorganic & Medicinal Chemistry Letters 2000, 10, 2325-2327. Article Link

 

 

      This page was last edited on 26 August, 2012